Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04592510
Other study ID # y66cyyg6
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 25, 2021
Est. completion date January 2022

Study information

Verified date June 2021
Source Cairo University
Contact Fatma Essam El-Deen
Phone 01150035515
Email fatma_essam@dentistry.cu.edu.eg
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Assessment of impact of covid-19 on pediatric dental practice during first, second and third wave among a group of pediatric dentists.


Description:

On the 11th of March, 2020, COVID-19 (SARS-CoV-2) was declared as a pandemic by the World Health Organization. SARS-CoV-2 is an unpredictable virus that is rapidly transmitting from one country to another, and unfortunately as of today, there is no effective medication or vaccine for the disease control. This virus has gone on to cause one of the most rapidly expanding pandemics with over 9 million people being infected worldwide including the pediatric population. Due to the unique nature of dentistry, most dental procedures generate significant amounts of droplets and aerosols, posing potential risks of infection transmission. Recent studies have demonstrated the role of the oral mucosa in COVID-19 infection, in addition to expressing the ACE2 receptor in salivary glands in the asymptomatic process in infected saliva, thus being one of the main sources of viruses. Clinical features of COVID-19 in children include fever and cough, but a large proportion of infected children appears to be asymptomatic and may contribute significantly to transmission. Therefore, it can be assumed that, at this stage in the pandemic, all children and their parents/carers are potentially infective with the potential of cross-infection to dental stuff, parents and the public. This has, in theory, an impact on medical and dental procedures that are Aerosol Generating Procedures.


Recruitment information / eligibility

Status Recruiting
Enrollment 345
Est. completion date January 2022
Est. primary completion date October 2021
Accepts healthy volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Egyptian pediatric dentists with at least Master's degree. - Work place located in Egypt. Exclusion Criteria: - Participants who refuse to participate.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Egypt Faculty of Oral and Dental Medicine, Cairo University Cairo

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

References & Publications (10)

Ahmadi H, Ebrahimi A, Ghorbani F. The impact of COVID-19 pandemic on dental practice in Iran: a questionnaire-based report. BMC Oral Health. 2020 Dec 3;20(1):354. doi: 10.1186/s12903-020-01341-x. — View Citation

Al-Halabi M, Salami A, Alnuaimi E, Kowash M, Hussein I. Assessment of paediatric dental guidelines and caries management alternatives in the post COVID-19 period. A critical review and clinical recommendations. Eur Arch Paediatr Dent. 2020 Oct;21(5):543-556. doi: 10.1007/s40368-020-00547-5. Epub 2020 Jun 16. Review. — View Citation

BaniHani A, Gardener C, Raggio DP, Santamaría RM, Albadri S. Could COVID-19 change the way we manage caries in primary teeth? Current implications on Paediatric Dentistry. Int J Paediatr Dent. 2020 Sep;30(5):523-525. doi: 10.1111/ipd.12690. — View Citation

Cook TM. Personal protective equipment during the coronavirus disease (COVID) 2019 pandemic - a narrative review. Anaesthesia. 2020 Jul;75(7):920-927. doi: 10.1111/anae.15071. Epub 2020 Apr 28. Review. — View Citation

Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S. Epidemiology of COVID-19 Among Children in China. Pediatrics. 2020 Jun;145(6). pii: e20200702. doi: 10.1542/peds.2020-0702. Epub 2020 Mar 16. — View Citation

Frauenfelder C, Butler C, Hartley B, Cochrane L, Jephson C, Nash R, Hewitt R, Albert D, Wyatt M, Hall A. Practical insights for paediatric otolaryngology surgical cases and performing microlaryngobronchoscopy during the COVID-19 pandemic. Int J Pediatr Otorhinolaryngol. 2020 Jul;134:110030. doi: 10.1016/j.ijporl.2020.110030. Epub 2020 Mar 30. — View Citation

Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis. 2020 Jun;20(6):689-696. doi: 10.1016/S1473-3099(20)30198-5. Epub 2020 Mar 25. — View Citation

Sinjari B, Rexhepi I, Santilli M, D Addazio G, Chiacchiaretta P, Di Carlo P, Caputi S. The Impact of COVID-19 Related Lockdown on Dental Practice in Central Italy-Outcomes of A Survey. Int J Environ Res Public Health. 2020 Aug 10;17(16). pii: E5780. doi: 10.3390/ijerph17165780. — View Citation

Sundaram M, Ravikumar N, Bansal A, Nallasamy K, Basavaraja GV, Lodha R, Gupta D, Odena MP, Ashwath RNR, Jayashree M; Intensive Care Chapter of Indian Academy of Pediatrics. Novel Coronavirus 2019 (2019-nCoV) Infection: Part II - Respiratory Support in the Pediatric Intensive Care Unit in Resource-limited Settings. Indian Pediatr. 2020 Apr 15;57(4):335-342. Epub 2020 Mar 29. — View Citation

Xu J, Li Y, Gan F, Du Y, Yao Y. Salivary Glands: Potential Reservoirs for COVID-19 Asymptomatic Infection. J Dent Res. 2020 Jul;99(8):989. doi: 10.1177/0022034520918518. Epub 2020 Apr 9. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Attitude of pediatric dentists toward treating patients in time of COVID-19. Measuring device by Questionnaire (Ahmadi, Ebrahimi & Ghorbani, 2020) and (Sinjari et al., 2020). The primary outcome is measured using 5-point likert scale scoring to evaluate pediatric dentists' attitudes 6 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04446065 - Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers Phase 2/Phase 3
Completed NCT04419025 - Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease Phase 2
Not yet recruiting NCT04400019 - Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM) Phase 2/Phase 3
Completed NCT04463004 - Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation Phase 2
Completed NCT04446429 - Anti-Androgen Treatment for COVID-19 N/A
Completed NCT04402957 - LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) Phase 2
Recruiting NCT04581148 - SARS-CoV2 Antibodies in Pediatric Patients (COVID-19)
Recruiting NCT04441372 - Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 Infection
Completed NCT04530604 - Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS) Phase 1
Terminated NCT04371978 - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Phase 3
Active, not recruiting NCT04635605 - Methylene Blue Treatment of COVID-19 Phase 2
Recruiting NCT04395599 - Risk of Air Contamination During Visceral Surgery in COVID19 Patients N/A
Recruiting NCT04472585 - Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients Phase 1/Phase 2
Active, not recruiting NCT04411433 - Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19 Phase 3
Completed NCT04359706 - Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19
Recruiting NCT04395794 - SARS-CoV-2 Disguise Study
Completed NCT04386551 - Detection of COVID-19 in Saliva Collection
Recruiting NCT04403269 - NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE Phase 2
Withdrawn NCT04379492 - A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19 Phase 2
Not yet recruiting NCT04377646 - A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers Phase 3